Navigation Links
Researchers Offer Explanation for Actos Bladder Cancer Risk
Date:7/3/2012

Orlando, FL (PRWEB) July 03, 2012

The Actos Bladder Cancer Center is alerting patients who have taken the drug Actos for their diabetes that researchers have identified an explanation for the drug’s link to bladder cancer. Legal help is still available for those just discovering they have been affected.

Anyone who has experienced symptoms of bladder cancer after taking Actos is encouraged to visit their doctor and speak with a lawyer about their legal rights as soon as possible.

For over a year, drug safety experts have warned that long-term use of Actos may be associated with bladder cancer. On June 10, 2011, CBS News reported that Germany and France banned Actos prescriptions after a study indicated long-term use could increase bladder cancer occurrences by as much as 40%. The FDA followed up on June 15, 2011 by issuing its own alert about the drug.

This April, the Canadian Press also reported that Health Canada had issued a warning after a study there showed a greater than 40% increased risk of bladder cancer from Actos.

Most recently, the British Medical Journal published a study on May 31, 2012 by researchers at McGill University in Montreal showing the increased bladder cancer risks from long-term Actos use may actually be as high as 83%.

The study found that the risk was specific to those taking Actos, and increased with use of the drug for more than two years. Also, this study was the first to specifically propose why Actos may increase risks of bladder cancer.

According to the research team at McGill, a possible explanatory mechanism for Actos bladder cancer risk is chronic irritation of the bladder from crystal formation caused by the drug. However, they cautioned that further research will be needed to establish this as causative.

Anyone who has suffered a bladder cancer or heart attack side effect after taking Actos is urged to speak with a lawyer about their legal options. According to Bloomberg News on March 13, 2012, Takeda Pharmaceuticals could face as many as 10,000 lawsuits in the U.S. from patients suffering serious side effects from their drug.

A federal Judicial Panel has consolidated all Actos lawsuits to a special multi-district federal court in Louisiana. The case is known as In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).

The Actos Resource Center cautions that, while the MDL court will expedite litigation for victims, it is important for anyone affected to choose a lawyer with experience in this specific type of case. The Actos Resource Center works only with qualified Actos lawyers who are actively involved in this litigation and have handled thousands of cases.

For more information on the research, warnings, side effects, a possible actos class action lawsuit and legal options relating to the drug Actos, or to speak with a lawyer, visit http://www.ActosLawsuitUpdate.com.

Read the full story at http://www.prweb.com/releases/actos/lawsuit/prweb9663606.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. Researchers develop a new cell and animal model of inflammatory breast cancer
3. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
4. Researchers Find Gene Mutations That May Be a Key to Autism
5. Researchers find evidence of banned antibiotics in poultry products
6. NJ stroke researchers report advances in spatial neglect research at AAN Conference
7. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
8. Researchers Map Brain Regions Linked to Intelligence
9. Researchers ID Genes That May Determine Mental Illness
10. Researchers Develop Blood Test for Depression
11. University of Cincinnati researchers win $3.7M grant from US Department of Defense
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Pensacola, FL (PRWEB) , ... April 28, 2017 ... ... Tampa, Florida are conducting a pilot study of ActiGraph’s CentrePoint Data ... ActiGraph is a leading provider of clinical-grade wearable activity and sleep monitoring solutions ...
(Date:4/28/2017)... ... April 28, 2017 , ... NuevaCare, a leading home care ... Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades to its blog ... and read organized content on topics such as home care (generally) as well as ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement to create ... by the continuing support of the Jane and Leonard Korman Family Foundation. The ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American ... 2017 Public Leadership in Neurology Award (PLINA). The couple joins a prestigious list ... Vice President Walter Mondale, actor Michael J. Fox and former U.S. Attorney General ...
(Date:4/27/2017)... ... , ... Offering the purest product of its kind, Swissx Labs AG has ... than the market has seen before. Swissx uses proprietary strains of hemp plants grown ... process for extraction, to produce its CBD oil--maximizing its benefits for health and wellness. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... BOSTON , April 19, 2017  New research provides ... with advanced Parkinson,s, according to a study released today that ... 69th Annual Meeting in Boston , ... comes to the treatment of Parkinson,s disease, the oral drug ... of life and longevity. But as the disease progresses, the ...
Breaking Medicine Technology: